chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This patient received her 4 month vaccines per protocol. One day after receiving vaccines, she developed vomiting and diarrhea. 5 days after receiving vaccines, she was diagnosed with ileocolic intussusception which was reduced with air contrast enema under fluoroscopy on 9/3/19 with no complications or sequelae.
while reconstituting / the needle popped out from the syringe / some of the liquid got into the eye her eye; occupational exposure; This case was reported by a pharmacist via call center representative and described the occurrence of exposure via eye contact in a 45-year-old female patient who received Herpes zoster (Shingrix) (batch number X7Z52, expiry date 5th November 2022) for prophylaxis.   On 9th April 2021, the patient received Shingrix. On 9th April 2021, unknown after receiving Shingrix, the patient experienced exposure via eye contact and occupational exposure while preparing product for administration. On an unknown date, the outcome of the exposure via eye contact and occupational exposure while preparing product for administration were unknown.  Additional details were reported as follows: The patient received Shingrix that while reconstituting a Shingrix vaccine the needle popped out from the syringe and some of the liquid got into the eye her eye, this happened on the same day as reported which led to exposure via eye contact and occupational exposure while preparing product for administration. The reporter consented to follow up.
fatigue; Very low grade fever 99.8; headache; This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for Injection; Batch/Lot Number, and Expiration Date not reported) via an unspecified route of administration on an unspecified date, as dose 2, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced fatigue, very low grade fever 99.8, and headache on an unspecified date. It was reported that the events took place after use of product. The patient underwent lab tests and procedures which included body temperature: 99.8 fahrenheit on an unspecified date. The outcome of events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Terrible fever, achy, could not focus. Felt like an elephant was sitting on my chest for most of the night. Highly concerned about long term damage given chest pains.
The symptoms started 6/18 which were fatigue and loss of appetite. A week or 2 later she experienced cognitive  decline and per her doctors orders an MRI of the brain was completed. The result of which was the discovery of a butterfly glioblastoma brain tumor.  It is lethal and she has 4-6 months to live. The doctor stated it is about 3 months old.
pt presented for pre-op hx of physical & had a fading bruise from flu vax;no problems;
Night of vaccination developed severe headache. Next day had temp of 102.9. That night her left upper arm and axilla became very red. The next day - (2nd post vac. day) the arm was red, swollen, warm to touch and very painful. Went to ER and dx with cellulitis. Admitted for IV-VANCOMYCIN. Admitted to hospital 10/20/10 and DC 10/24/2010.
Nausea, vomiting, diarrhea, temperature of 97.7F, anorexia and rash. This is the 2nd pt with these symptoms in this lot of MMR II.
Expired dose administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 17-month-old male patient who received DTPa (Infanrix) (batch number 23T73, expiry date 30-APR-2023) for prophylaxis.   On 02-MAY-2023, the patient received the 4th dose of Infanrix. On 02-MAY-2023, an unknown time after receiving Infanrix, the patient experienced expired vaccine used (Verbatim: Expired dose administered). The outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 03-MAY-2023 The reporter was nurse administrator. The reporter reported that one of the nurses at their facility administered a dose of Infanrix, which had an expired. This was the patient's fourth dose in the series. At the time of reporting, the dose had not been repeated. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up.  The patient had received an expired dose of Infanrix, which led to expired vaccine used.
super sick; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of sickness in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced sickness (Verbatim: super sick).  The outcome of the sickness was not reported.   It was unknown if the reporter considered the sickness to be related to Shingles vaccine.     It was unknown if the company considered the sickness to be related to Shingles vaccine.   Additional Information: Gsk receipt date 18 Sep 2023 This case was reported by a consumer via interactive digital media. The patient was super sick after having vaccine. The patient assumed it was better than the shingles though.
Pt recv vax on 5/4/99; 4 hr post vax pt exp raised red maculo-papular rash w/ blanched areas on face & trunk, less sleeping & fussy
Pt reports having severe nausea for the first 24 hours, one week later her arm knotted up, had redness, heat, was itchy and painful to injection site that lasted for one week. Then started having constant pain in upper arm area since then (from shoulder to elbow area), pain becomes worse with use, throbbing pain and also shooting pain down entire arm at times. Did not call her doctor or seek medical attention. Arrived at appointment time on 2/1/21 for second dose but refuses second dose, reports she came only to report her symptoms.
COVID-19; Diagnosed with breast cancer; This serious case was reported by a consumer via call center representative and described the occurrence of covid-19 in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 06-AUG-2022, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced covid-19 (Verbatim: COVID-19) (serious criteria hospitalization) and breast cancer (Verbatim: Diagnosed with breast cancer) (serious criteria GSK medically significant). The outcome of the covid-19 and breast cancer were not reported.   It was unknown if the reporter considered the covid-19 and breast cancer to be related to Shingrix.     It was unknown if the company considered the covid-19 and breast cancer to be related to Shingrix.   Additional Information: GSK Receipt Date: 31-MAY-2023 The patient self-reported this case. The reporter stated that she had not yet receive her second dose of Shingrix because she was diagnosed with breast cancer which she had a lumpectomy for. The patient also had COVID-19 for which she was hospitalized.  Reporter did not provide any additional details.  The reporter did not consent to follow up.
Information has been received from a registered medical assistant concerning an 80 year old male patient with drug hypersensitivity to REGLAN and NIASPAN and no illness at time of vaccination who on 06-JAN-2011, was vaccinated SQ in the left deltoid with the first dose of ZOSTAVAX (Merck) (lot# 669187/1543Z) at 9:20. On 15-JAN-2011 at 20:00, the patient first noticed nodular, painful rash. The registered medical assistant stated that the eruption was contained on the right arm, the right trunk, the right shoulder/scapula area, which met the criteria for shingles eruption. The patient also complained of pain in areas of eruption and his skin was very sensitive. The patient's evaluation at the office was on 20-JAN-2011. The patient was treated with VALTREX and pain medication. At the time of the report, the patient's outcome was unknown. Additional information has been requested.
Patient received 1st COVID vaccine on 2.12.21. Reported to local ER with chest pain and increased ShOB on 2.22.21. Found to be positive for COVID, elevated troponin. Transferred to medical center. Patient was mildly hypoxic on the floor but never required more than 2L nasal prongs. Patient is currently on dialysis. Patient received dexamethasone therapy only while on the floor. Discharged home on 3.4.2021.
Sore throat before vaccine.  Muscle and body aches after the vaccine.  Headache after the vaccine.  Started second menstrual cycle the day after the vaccine. Last menstrual cycle was a week before the vaccine. Second menstrual cycle started the day after the vaccine. Heavy cramps, light to medium bleeding.
Pt. was complaining of dizziness to mom Mom and learned on Moms shoulder - pt. then passed out and Mom laid pt. on floor, pt. starting having seizure like activity.
On April 14th started with sore throat and the next day still had sore throat and low grade fever, the next day sore throat, low grade fever, and sinus pressure, the next day sore throat, low grade fever, sinus pressure, and fatigue kicked in as well. I was symptomatic for 8 days.
Intussusception 9/26/07-spoke with reporter's office requested vac rec-intussusception resolved with barium enema while traveling in India.  9/27/07-reporter called-returned from India first x-rays indicated possible intussusception, in India visited a second physician and had another series of x-rays which did not demonstrate intussusception. No records received by the reporter from India. Misdiagnosed Intussception.
Admitted for COVID. Fully vaccinated x3. Received remdesivir, zinc, rocehpin, zitrhomax. Improved and discharged home with home health.
Information has been received from a Family Nurse Practitioner concerning a female who was vaccinated with GARDASILl vaccine (yeast). The patient received two doses of GARDASIL vaccine (yeast) and developed urticaria after the second dose. The patient was not going to receive the third dose. No other information was reported. Additional information has been requested.
She was given a Pfizer bivalent vaccine ages 5-11 years instead of her primary series 2nd  monovalent vaccine. No reported adverse events by parents.
It was reported that a pt (1 of 3) received a Tripedia vaccination, date not specified. Reportedly, 24-48 hours, post vax, the pt developed a local reaction of swelling, redness and erythema at the injection site. Further information is requested. From additional correspondence received on 5/7/01, it was reported that the pt recovered from this experienced. Additional pt, vaccine, vaccine administrator and responsible physician information was also provided.
Starting the afternoon I had the shot (about 8 hours later)  I began with body aches, and headache. Throughout the night I had a SEVERE headache, like nothing I have ever had before along with fever, chills, and body aches. The following day I still had a severe headache with fever and chills and extreme fatigue. 48 hours later all the symptoms were gone with the exception of the headache which lingered another 12 hours.  I am still 3 months later having issues with daily headaches, not sure if it is related or coincidence but it is not a normal thing for me to have headaches like this.
prolonged crying >3 hrs & high pitched cry the day p/vax; treated w/APAP;
Covid19 vaccine for 11 years and older was diluted with 1.3ml of dilution was given to patient under 11 years old Pt did received the correct dose of vaccine 10mcg in 0.2ml . No adverse effect reported after 15 minutes of vaccine administration
I received my second Moderna booster for COVID-19 on 6/11/2022. On the evening of 9/6/2022, I developed a persistent cough. I thought it was caused by allergies, and I had trouble sleeping that night. (As a matter of fact, I have had trouble sleeping ever since.). On 9/7/2022, I called my PCP's office to try to book an appointment, but they were booked up. They offered to do a telehealth visit, but I declined, as I have a number of allergies anyway. Through the following days, my cough became more persistent, and I developed a runny nose. On the night of 9/9/2022, I took a home COVID-19 test and got a positive result. On 9/10/2022, I went to an urgent care, and they gave me a number to call to inquire about getting medication. I called the number, and I was prescribed PAXLOVID, which I started taking that night. While I was at the urgent care, I also underwent a rapid test for COVID-19 and got another positive result. Since I've begun taking the PAXLOVID, the symptoms have begun diminishing. It got rid of the runny nose, though I still have a cough. I'm taking OTC EQUATE cold and flu medicine and ADVIL, and they are helping ease the cough.
Pt developed headache, myalgias and fatigue week of 2/22/21 Pt developed RUQ pain on 3/1/21  Subsequently developed vesicular rash on RUQ and and back along dermatomes 3/2/21  Diagnosed with Shingles on 3/3/21 -started on gabapentin and valacyclovir
A non-serious spontaneous report of FLUMIST administered to couple in their 70s was received from a health professional concerning an elderly male. Neither relevant medical history nor concomitant medications have been reported for this patient. In Sep-2011, a 70 year old patient received FLUMIST. There was no adverse event associated with this medication error; therefore, treatment and reporter causality assessments are not applicable, and the event is considered resolved.
Pt devel redness @ inject site, swelling of arm, & fever 100.4 p/receiving Td; These sx were treated w/Advil & the application of ice packs; 05FEB91 pt began tx w/Pred & DPH; Red areas on the arm were still noted on 21FEB91;
burning foot; itching in right foot; This spontaneous case was reported by a consumer and describes the occurrence of BURNING SENSATION (burning foot) and PRURITUS (itching in right foot) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 040B21A and 002B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included GLYBURIDE, LINAGLIPTIN (TRAJENTA), INSULIN DETEMIR (LEVEMIR) and LISINOPRIL for an unknown indication.   On 20-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Apr-2021, the patient experienced BURNING SENSATION (burning foot) and PRURITUS (itching in right foot). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Burning foot and Itching, at a dose of 1 dosage form. At the time of the report, BURNING SENSATION (burning foot) and PRURITUS (itching in right foot) outcome was unknown. Not Provided          Concomitant medications include vitamins.
Pt returned to clinic 2 hours and 45 minutes following an injection of yellow fever and Hep A. Pt presented with urticaria, over whole body, tightness in chest, ? breathing. Pt treated with epi and ?, transported to ER.
Case number PHEH2015US022241 is an initial report received from a consumer via patient oriented program on 25 Oct 2015. This report refers to an 85 year old female patient. Her current condition included blood pressure, unspecified heart condition and hospitalization due to congestive heart failure last week. Her concomitant medications were amlodipine, NORVASC, JANUVIA, metolazone, LOPRESSOR, fenofibrate, Baby aspirin and potassium used for the treatment of blood pressure and unspecified heart condition. She was treated with LASIX (other manufacturer) for congestive heart failure at an unknown dose from an unspecified date when she was hospitalized. She also received seasonal influenza vaccine (manufacturer and batch number: not reported) on an unknown date (same time as of LASIX). On an unspecified date she experienced difficulty in breathing when she was in the hospital. Action taken with LASIX was not reported. The events outcome was not reported. The events were reported as serious. The causality of the event was not reported. The reporter stated that she might be taking Novartis medications, but was not certain. No further information was provided.
Nursing home staff member vaccinated at mass vaccination event for nursing home residents and staff on 12/18/2020. Developed headache, cough, runny nose on 12/26/2020. Tested + for COVID-19 on 12/28/2020. Recovering well at home. No hospitalization or ED visits.
pericarditis, diagnosed by Dr. cardiologist.  confirmed by Dr., family doctor and Dr., Pulmonologist. had covid shots february 24,2021 and March 17, 2021.  Around April 7th started feeling like someone was sitting on my heart.  I had a hard time breathing and was in pain. finally went for covid testing at 365md on april 19, 2021 and they sent me to hospital.  went to Dr. cardiologist on April 20,2021 and was diagnosed as Pericarditis.
laryngitis; fever; myalgia; fatigue; This case was reported by a physician via call center representative and described the occurrence of laryngitis in a 66-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 25th August 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 2 months after receiving Shingrix, the patient experienced laryngitis, fever, myalgia and fatigue. On an unknown date, the outcome of the laryngitis, fever, myalgia and fatigue were unknown.   It was unknown if the reporter considered the laryngitis, fever, myalgia and fatigue to be related to Shingrix.  Additional details were provided as follows: The patient received a dose of Shingrix at the pharmacy. In 2019, the patient experienced laryngitis, fever, myalagia and fatigue. Additional information not provided.
Moderate joint aches and nausea. Started 18 hours after the vaccine and lasted 24 hours.  Very sore right arm lasting about 72 hours.
Developed cough within minutes of injection, followed by facial flushing and severe wheezing with resp distress and hypoxia within 5 min of injection. TX IM Epi, Albuterol neb, Benadryl and IM Steroids.  02/27/2007 Spoke with reporter.  Box 10 and 11 information received and recorded in VAERS. 02/27/2007 MR received for office visit of 02/19/2007 for well child 15 month visit. PE WNL.  DTaP received.  Child immediately began coughing slightly.  Mom returned shortly with child with child wheezing and in distress.  No hives.  O2 sat 91-93%.  Face flushed without edema.  Txd with po Benadryl, injectable steroids, Epi-pen, and albuterol nebs.  O2 sats returned to normal 98% within a few minutes.  Observed 1 1/2 hours and  discharged home. DX: Anaphylactic Reaction. Unlikely DTaP, but no other known exposure.
Flu-like symptoms, runny nose, sinus congestion, epistaxis (unilateral), malaise, difficulty with sleeping.
Mother reported onset of fever the day of vaccine. Fever was unrelieved by Tylenol and had no family thermometer. No sponge bath. Normal vomiting and normal intake. Temperature was 104.9F (axillary) at 11:00 on 8/14/01 at the clinic. Sweating child was given Tylenol and clothes removed and sponge bathed. Treatment recommended: alternate acetaminophen and ibuprofen every 3 hours. Child went with mother to see doctor in Mexico on 8/15/01 and received unknown injection and Febrax supps. Situation resolved by 8/16/01.
67 yo male with renal/pancreas transplant (1997), metastatic prostate CA, PAD s/p fem-tib bypass 2015, R fem-pop bypass 2018 admitted for CABG x3 8/16/21. Immunosuppressed on mycophenolate mofetil, cyclosporine, prednisone.  Found to have COVID-19 8/27/21.  Negative admission testing.  He is fully vaccinated (dose 1 on and dose 2 on .  He is unaware of any illnesses in his household or visitors.  Denies respiratory symptoms.  No SOB, cough.  Had a low grade temp 8/25/21.  Has had a leukocytosis which seems like prompted the test.  Put on cefepime and vancomycin day 3 for empiric coverage.  No evidence of PNA. Casirivimab/imdevimab infusion completed 8/28.
back hurts; arm hurt and was sore; light headache; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (arm hurt and was sore), HEADACHE (light headache) and BACK PAIN (back hurts) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Feb-2021, the patient experienced INJECTION SITE PAIN (arm hurt and was sore) and HEADACHE (light headache). On 08-Feb-2021, the patient experienced BACK PAIN (back hurts). At the time of the report, INJECTION SITE PAIN (arm hurt and was sore), HEADACHE (light headache) and BACK PAIN (back hurts) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 22-Apr-2021: Received TCR patients email address was  provided.He also stated that he never had back  pain following the vaccine.
The day after the injection I experienced shortness of breath and a pounding heart, especially going upstairs.  After several days, it became so severe that I had to lie down to catch my breath after climbing stairs or doing anything remotely strenuous.  It would resolve itself after a few minutes of rest.  It continued for 6 days and then stopped on the 7th day.  I felt fine the day of the injection.   I plan to follow up with my primary doctor.  As of now, it appears to be completely resolved but I will not take the second dose for fear of a bad reaction.
day after shot. Woke up at 3:00 Am with severe pain in my right arm with redness and swelling around the shot area.
presented to his local emergency department with complaints of shortness of breath. In the ED he was found to be COVID-19 positive,
Approximately 75 minutes after vaccine had significant shortness of breath, extreme fatigue (difficulty walking to the bathroom). Over the next week and a half, blood pressure and heart rate swung widely (outside of normal range). Heart rate periodically dropped down into 30-40 range. Experienced whiteouts.
INAPPROPRIATE AGE AT VACCINE ADMINISTRATION; This spontaneous report received from a consumer concerned a 16 year old male. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1820095 expiry: 18-AUG-2021) dose was not reported, administered on 08-JUL-2021 for prophylactic vaccination. No concomitant medications were reported. On 08-JUL-2021, the subject experienced inappropriate age at vaccine administration. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of inappropriate age at vaccine administration was not reported. This report was non-serious.
New onset DVT of Thrombus in the right popliteal vein is present. Thrombus in the right peroneal vein is present.
Patient has medical history of chronic kidney disease; Traveled out of sate three weeks prior to 7/7/2021 Developed cough two week later C19 outbreak at her church and her Mother tested positive Currenlty hospitalized since 7/7/2021
Information has been received from a pharmacist concerning a hospitalized patient who on an unknown date was vaccinated with a dose of PNEUMOVAX 23, lot # was not specified. The pharmacist stated that the patient's blood pressure dropped, developed a rash and fluids were ordered after receiving the vaccine. The patient was already in the hospital because of a different issue when this occurred and their discharge was delayed. Patient's outcome is unknown. Additional information is not expected.